« It has always been a dream of mine to fulfill unmet medical needs often overlooked by pharmaceutical laboratories, a key area of interest being emergency contraception. As a result, myself and some key partners dared to invest personal funds to embark on achieving this goal – and so our story began. Today, HRA Pharma is proud to share its success not only in the area of emergency contraception but in the broader areas of women’s health and endocrinology. »
André Ulmann, Founder – Chairman
A physician at the renowned Necker hospital in Paris, France, André Ulmann started HRA Pharma in 1996 following an esteemed career as a pharmaceutical company executive.
The NorLevo® years
During the first few years of business, Dr. Ulmann built up a small team of professionals in Paris that pioneered HRA Pharma’s first product, NorLevo® (levonorgestrel) – an emergency contraceptive pill. Launched in France in 1999, it was approved for marketing throughout Europe one year later. This product generated such strong interest from a public health perspective that the French authorities immediately enacted policy to make it widely accessible to patients. As a result, it became the first hormonal contraceptive product to be made available without prescription, and the first to be made available free of charge to under -18 years old.
NorLevo® is now available in over 50 countries worldwide.
Innovating today for tomorrow
Today, HRA Pharma is a leading European pharmaceutical company with a global product presence and local operations in nine European countries. Over the past decade the company has significantly grown its business in the fields of women’s health and endocrinology.
The company's women’s health products include ellaOne® , an ulipristal acetate-based emergency contraceptive, NorLevo®, a levonorgestrel-based emergency contraceptive, Clareva Gel™ a symptomatic treatment of genital herpes, Cicatridine® for intimate health (vaginitis, vaginal injury, vaginal dryness) and Mona Lisa®, a copper contraceptive IUD (IntraUterine Device).
In the field of endocrinology, HRA Pharma commercializes Lysodren® (mitotane), an orphan drug for the treatment of advanced adrenal cortical carcinoma (ACC). In order to assist healthcare professionals in the treatment of patients with this disease, HRA Pharma has also launched LYSOSAFE Service, a free therapeutic monitoring service that helps physicians optimize Lysodren® treatment.
HRA Pharma’s endocrinology portfolio also includes two treatment options for endogenous Cushing's Syndrome: Metopirone® (metyrapone), a cortisol synthesis inhibitor indicated for the management of Cushing's syndrome and as a diagnostic drug for pituitary function testing and the differential diagnosis of Cushing's syndrome; and Ketoconazole HRATM (ketoconazole).